PharmaCyte Biotech raises $70M in registered direct offering and private placement

PharmaCyte Biotech, Inc.

Gross proceeds ~$70M from sale of 8.43M shares and 5.57M pre-funded warrants at $5.00 per share.
Unregistered Series A warrants for 7M shares at $5.00, exercisable immediately, 5-year term.
Net proceeds to address FDA clinical hold on IND for Phase 2b trial in pancreatic cancer and fund trial.
H.C. Wainwright acting as exclusive placement agent; closing expected on or about August 23, 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.